The metabolic effects of drugs used for the treatment of polycystic ovary syndrome

類似資料

• Is there a link between polycystic ovary syndrome and non-thyroidal illness syndrome?
  著者:: Karaköse, Melia, 等
  出版事項: (2013)
• The assessment of thyroid autoantibody levels in euthyroid patients with polycystic ovary syndrome
  著者:: Hepşen, Sema, 等
  出版事項: (2018)
• A rare coexistence of non-functional adrenocortical carcinoma and multicentric papillary thyroid microcarcinoma: a case report
  著者:: Karakose, Melia, 等
  出版事項: (2013)
• Frequency of nodular goiter and autoimmune thyroid disease and association of these disorders with insulin resistance in polycystic ovary syndrome
  著者:: Karaköse, Melia, 等
  出版事項: (2017)
• Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome
  著者:: Karbek, Basak, 等
  出版事項: (2014)